Arch Therapeutics Reports Favorable Results for AC5 Surgical Hemostatic Device in Biocompatibility Testing Required for CE Mark
March 14, 2016 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Mar 14, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ ("AC5™"), has obtained...
Arch Therapeutics to Present at the 28th Annual Roth Capital Conference on Tuesday, March 15, 2016
March 10, 2016 08:20 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Mar 10, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
Arch Therapeutics Receives ISO 13485 Certification for AC5
March 09, 2016 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Mar 9, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ ("AC5™"), today announces...
Arch Therapeutics Clinical Trial Actively Enrolling Patients and Providing Investigational Treatment
March 07, 2016 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Mar 7, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ ("AC5™"), has initiated...
Arch Therapeutics to Present at the SeeThruEquity Annual Innovations Investor Conference in Miami, Florida on Monday, February 22, 2016
February 17, 2016 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Feb 17, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
Arch Therapeutics to Present at the Source Capital Group's 2016 Disruptive Growth & Healthcare Conference on Wednesday, February 10, 2016
February 08, 2016 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Feb 8, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
Arch Therapeutics to Present at the BIO CEO & Investor Conference on Monday, February 8, 2016
February 03, 2016 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Feb 3, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
Arch Therapeutics to Present at the Biotech Showcase(TM) 2016 Conference on January 12th 2016
January 04, 2016 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Jan 4, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device™...
Arch Therapeutics Receives Clearance to Initiate Clinical Trial in Europe
December 16, 2015 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Dec 16, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device™...
Arch Therapeutics Receives Notice of Allowance for New Patent in the United States
December 03, 2015 16:02 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Dec 3, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...